Detalhe da pesquisa
1.
Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.
Br J Haematol
; 204(4): 1293-1299, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38263627
2.
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
Blood
; 139(9): 1330-1339, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34570879
3.
Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias.
Eur J Haematol
; 112(4): 538-546, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38044594
4.
Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma.
Eur J Haematol
; 112(6): 975-983, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38382632
5.
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
Br J Haematol
; 200(1): 54-63, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36120837
6.
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
Haematologica
; 108(1): 98-109, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35833303
7.
Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma.
Eur J Haematol
; 110(6): 626-632, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36752328
8.
Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma.
Eur J Haematol
; 109(5): 559-565, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054450
9.
Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination.
Eur J Haematol
; 109(5): 458-464, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35810359
10.
Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis.
Transpl Infect Dis
; 24(2): e13792, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35030267
11.
Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM).
Eur J Haematol
; 107(6): 602-608, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34378251
12.
Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Virol J
; 17(1): 154, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33059711
13.
Chimeric Antigen Receptor T-Cell Access in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Association of Access with Social Determinants of Health and Travel Time to Treatment Centers.
Transplant Cell Ther
; 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38697294
14.
Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review.
Front Oncol
; 14: 1383730, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38665946
15.
Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma.
Transplant Cell Ther
; 30(3): 298-305, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38142943
16.
Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation.
Leuk Lymphoma
; 65(4): 493-502, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38164945
17.
Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: Insights from a real-world experience.
Transpl Immunol
; 84: 102039, 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513813
18.
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
Transplant Cell Ther
; 30(3): 308.e1-308.e13, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38151105
19.
Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation Over the Last 15 Years: A Systematic Review.
Hematol Oncol Stem Cell Ther
; 17(2): 88-94, 2024 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38560970
20.
Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated myelodysplastic syndrome: A systematic review and meta-analysis.
Crit Rev Oncol Hematol
; 196: 104310, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38423375